Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001209191-23-012875

Options or other derivatives

  • Chief Financial Officer acquired 640,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Derivatives
Alspaugh Jonathan Chief Financial Officer 2023-02-23 Grant or award · Employee Stock Option (right to buy) +640,000 640,000 D
Loading xslF345X03/doc4.xml…